BRISTOL-MYERS SQUIBB COMPANY Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of -$8.00 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2021-10-27
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2021-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2015 was $30.00M, a 34.78% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2014 was $46.00M, a 13.21% decline from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2013 was $53.00M, a 8.16% increase from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2012 was $49.00M, a 16.95% decline from fiscal 2011.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | -$8.00M 10-Q · filed 2021-10-27 | ||
| 2021-06-30 | -$8.00M 10-Q · filed 2021-07-28 | |||
| 2015-12-31 | $30.00M 10-K · filed 2016-02-12 | |||
| 2014-12-31 | $46.00M 10-K · filed 2016-02-12 | |||
| 2013-12-31 | $53.00M 10-K · filed 2015-02-13 | |||
| 2012-12-31 | $49.00M 10-K · filed 2014-02-14 | |||
| 2011-12-31 | $59.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |